PREPARATION OF A PHARMACEUTICAL COMPOSITION OF OLODATEROL AND BUDESONIDE

1 . A liquid, propellant-free pharmaceutical formulation comprising:

(a) budesonide and olodaterol;

(b) a solvent; and

(c) a pharmacologically acceptable solubilizing agent;

wherein the solubilizing agent is selected from the group consisting of a cyclodextrin derivative or a salt thereof, and combinations thereof.

wherein the pharmaceutical formulation has a pH ranging from about 2.0 to about 6.0.

2 . The pharmaceutical formulation according to claim 1 , wherein budesonide is present in an amount ranging from about 1 mcg/ml to about 100 mcg/ml.

3 . The pharmaceutical formulation according to claim 1 , wherein the olodaterol is present in an amount ranging from about 2 mcg/ml to about 500 mcg/ml.

4 . The pharmaceutical formulation according to claim 1 , wherein the solvent is a water substantially free of other solvents.

5 . The pharmaceutical formulation according to claim 1 , wherein the solubilizing agent is sulfobutylether β-cyclodextrin sodium.

6 . The pharmaceutical formulation according to claim 5 , wherein the solubilizing agent is present in an amount ranging from about 1 g/100 ml to about 40 g/100 ml.

7 . The pharmaceutical formulation according to claim 5 , wherein the solubilizing agent is present in an amount ranging from about 0.04 g/4 ml to about 1.6 g/4 ml.

8 . The pharmaceutical formulation according to claim 1 , further comprising a pharmacologically acceptable preservative selected from the group consisting of benzalkonium chloride, benzoic acid, and sodium benzoate.

9 . The pharmaceutical formulation according to claim 8 , wherein the pharmacologically acceptable preservative is present in an amount ranging from about 0.08 mg/4 ml to about 12 mg/4 ml.

10 . The pharmaceutical formulation according to claim 8 , wherein the pharmacologically acceptable preservative is benzalkonium chloride in an amount of about 0.4 mg/4 ml.

11 . The pharmaceutical formulation according to claim 1 , further comprising a stabilizer selected from the group consisting of edetic acid (EDTA), edetate disodium, edetate disodium dihydrate, and citric acid, and wherein the stabilizer is present in an amount ranging from about 0.04 mg/4 ml to about 20 mg/4 ml.

12 . The pharmaceutical formulation according to claim 1 , further comprising sodium chloride in an amount ranging from about 0.1 g/100 ml to about 0.9 g/100 ml.

13 . A method for administering the pharmaceutical formulation according to claim 1 , comprising nebulizing a defined amount of the pharmaceutical formulation with an inhaler by using pressure to force the pharmaceutical formulation through a nozzle to form an inhalable aerosol.

14 . The method according to claim 13 , wherein the defined amount of the pharmaceutical formulation is less than about 8 microliters of the pharmaceutical formulation.

15 . The method according to claim 13 , wherein the average particle size of the aerosol is less than about 15 micron.

16 . A method of treating asthma or COPD in a patient, comprising administering to the patient the pharmaceutical formulation according to claim 1 .

17 . The method of claim 16 , wherein the pharmaceutical formulation is administered at a therapeutically effective dose of budesonide ranging from about 1 μg to about 100 μg and a therapeutically effective dose of olodaterol ranging from about 5 μg to about 500 μg.

18 . The pharmaceutical formulation according to claim 1 , wherein budesonide is present in an amount of about 500 μg/mL.

19 . The liquid, propellant-free pharmaceutical formulation of claim 1 comprising:

an aqueous solution of:

(a) budesonide in an amount of about 1 μg/mL to about 1000 m/mL;

(b) olodaterol in an amount of about 2 μg/mL to about 500 m/mL;

(c) sulfobutyl ether β-cyclodextrin sodium in an amount of about 1 g/mL to about 40 g/100 ml;

(d) sodium chloride in an amount of about 0.1 g/100 mL to about 0.9 g/100 mL; and

(e) citric acid in an amount sufficient to adjust the pH to about 4.0.

20 . The liquid, propellant-free pharmaceutical formulation of claim 1 comprising:

an aqueous solution of:

(a) budesonide in an amount of about 1 μg/mL to about 1000 μg/mL;

(b) olodaterol in an amount of about 2 μg/mL to about 500 μg/mL;

(c) sulfobutyl ether β-cyclodextrin sodium in an amount of about 1 g/mL to about 40 g/100 mL;

(d) sodium chloride in an amount of about 0.1 g/100 mL to about 0.9 g/100 mL; and

(e) hydrochloric acid in an amount sufficient to adjust the pH to about 5.0.

21 . The liquid, propellant-free pharmaceutical formulation of claim 1 comprising:

an aqueous solution of:

(a) budesonide in an amount of about 50.9 mg/100 mL;

(b) olodaterol in an amount of about 1.8 mg/100 mL;

(c) sulfobutyl ether β-cyclodextrin sodium in an amount of about 9.6 mg/mL; and

(d) citric acid in an amount sufficient to adjust the pH to about 4.0

22 . The liquid, propellant-free pharmaceutical formulation of claim 1 comprising:

an aqueous solution of:

(a) budesonide in an amount of about 50.9 mg/100 mL;

(b) olodaterol in an amount of about 1.8 mg/100 mL;

(c) sulfobutyl ether β-cyclodextrin sodium in an amount of about 9.6 mg/mL; and

(d) hydrochloric acid in an amount sufficient to adjust the pH to about 5.0